Patients with relapsed or refractory (R/R) multiple myeloma who received a combination of teclistamab, a bispecific monoclonal antibody, and daratumumab, a CD38-directed monoclonal antibody, were 83% ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback